A5075886635- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Drug Transport and Resistance Mechanisms
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- PI3K/AKT/mTOR signaling in cancer
- Cancer therapeutics and mechanisms
- Vector-borne infectious diseases
- Pharmacological Effects and Toxicity Studies
- Insect and Pesticide Research
- Insect and Arachnid Ecology and Behavior
- Viral Infections and Vectors
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Antiplatelet Therapy and Cardiovascular Diseases
- Calcium signaling and nucleotide metabolism
- Peripheral Artery Disease Management
- Lymphatic System and Diseases
- Glycosylation and Glycoproteins Research
- Acute Myeloid Leukemia Research
- Heavy Metal Exposure and Toxicity
- Arsenic contamination and mitigation
- Paraoxonase enzyme and polymorphisms
Copernicus Memorial Hospital
2005-2024
Medical University of Lodz
2005-2024
Kerala Veterinary and Animal Sciences University
2020-2024
Wroclaw Medical University
2014-2022
Wroclaw Research Centre EIT+ (Poland)
2016-2017
Ruhr University Bochum
2017
Vita-Salute San Raffaele University
2009-2012
San Raffaele University of Rome
2011
Palmetto Hematology Oncology
2009
The mammalian target of rapamycin (mTOR) kinase is a key regulator cell growth and proliferation. Overexpression the mTOR signaling pathway has been described in several tumor cells, including majority acute myeloid leukemia (AML) cases. anti-tumor efficacy inhibitors was shown preclinical clinical studies. In AML, however, potential antineoplastic effect received little attention thus far. this in-vitro study human AML line, HL-60, we aimed to assess antileukemic activity (RAPA), an...
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL patients continue relapse, sooner or later, most require subsequent lines treatment. This report presents the cases four relapsed with classic who were treated vemurafenib (mostly at low dose 240 mg twice daily 16 weeks) combined rituximab after failure several therapy including without...
Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% cases and continuous 20% patients.
Inherited differences in xenobiotic transport and metabolism may play an important role the development of adult acute myeloid leukemia (AML) response to chemotherapy. An ATP-binding cassette (ABC) family transporter P-glycoprotein (P-gp or ABCB1), encoded by ABCB1 (MDR1) gene, is involved protection against xenobiotics multi-drug resistance. The aim this study was investigate potential involvement gene exon 26 3435C>T single nucleotide polymorphism (SNP) genetic susceptibility AML...
Introduction . A typical symptom of chronic lower-limb ischaemia is pain, which occurs during walking forcing the patient to stop, intermittent claudication (IC). Exercise rehabilitation basic form treatment for these patients. Aim. The aim this study was compare effectiveness three types physical training programmes conducted over a 12-week period in patients with arterial insufficiency. Materials and Methods Ninety-five people qualified 3-month supervised motor programme, times week....
(1) Background: The aim of this dynamic-LC/MS-human-serum-proteomic-study was to identify potential proteins-candidates for biomarkers acute ischemic stroke, their changes during phase stroke and define novel drug-targets. (2) Methods: A total 32 patients (29-80 years) with were enrolled the study. control group constituted 29 demographically-matched volunteers. Subjects presented clinical symptoms lasting no longer than 24 h, confirmed by neurological-examination and/or new cerebral...
Background: Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoid malignancy. The majority of patients are asymptomatic and HCL usually diagnosed incidentally during routine blood counts. In symptomatic patients, typical symptoms related to pancytope-nia splenomegaly. this review we present, clinical in with HCL. Methods: A literature search was conducted PubMed, Web Science, Google Scholar for articles concerning hairy leukemia, cutis, bone lesions, neurological manifesta-tions,...
BACKGROUND The treatment of patients with acute leukemia, who due to their religious beliefs refuse accept blood transfusion, is a great challenge for hematologists. CASE REPORT We present case pre‐T‐lymphoblastic leukemia in Jehovah's Witness did not transfusion during chemotherapy. Standard induction and consolidation chemotherapy was used (according the PALG ALL‐6 regiment). RESULTS During cycles, darbepoietin alfa, intravenous iron, total parenteral nutrition administered. Extreme (Hb...
The aim of this study was to determine the feasibility, efficacy and toxicity combined therapy consisting cladribine (2-CdA), mitoxantrone cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL). Thirty six patients, 14 mantle cell (MCL), 10 diffuse large B-cell (DLBCL), 5 follicular (FL), 3 small lymphocytic (SLL), 4 T-cell were enrolled study. CMC protocol consisted 2-CdA at a dose 0.12 mg/kg 2-hour infusion on days 1 through 3, mg/m2 i.v. day...
The differences in clinical course of chronic lymphocytic leukemia could have an impact on variations a patient’s response to therapy. Our published results revealed that thermal transition (95 ± 5°C) differential scanning calorimetry profiles appear be characteristic for the advanced stage CLL. Moreover, decrease/loss this nuclei from leukemic cells exposed drugs ex vivo indicate their diverse efficacy. It seems lack changes profile predict drug resistance. In study, we demonstrate obtained...